Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung Cancer

This article explores the treatment options for extensive-stage small cell lung cancer, including recent approvals of combination regimens, and considers treatment consequences that can lead to further complications.

Dr. Jared Weiss of the University of North Carolina Lineberger Comprehensive Cancer Center considers treatment challenges and unmet needs in the current standard-of-care management of extensive-stage small cell lung cancer.

In this companion article, Dr. Jared Weiss provides key insights into recent advancements in the standard of care for extensive-stage small cell lung cancer and examines challenges affecting treatment.

This article reviews the impact of chemotherapy-induced myelosuppression associated with current standard-of-care management of extensive-stage small cell lung cancer and examines new and emerging therapies that may have the potential to address unmet needs.

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.

In this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.

This article presents key findings on the safety and efficacy of trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. As of May 1, 2022, Dr. Malhotra is no longer with Rutgers Cancer Institute; she is now affiliated with City of Hope.

In this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

This article provides an overview of the role of MDM2 and MDMX as drivers of malignancy and examines the potential chemoprotectant benefit of the dual MDM2/MDMX inhibitor ALRN-6924 observed in 2 phase 1b clinical trials of patients with small cell lung cancer and non-small cell lung cancer.

In the fourth interview of the series, Dr. Estelamari Rodriguez from the University of Miami Health System considers unmet needs in extensive-stage small cell lung cancer and discusses the role of reactive and proactive approaches to the management of chemotherapy-induced myelosuppression.

In this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.

In the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.

Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.

In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.

Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).

In this companion article, Dr Paul Bunn discuss the implications from the pooled results of trilaciclib on chemotherapy induced myelosuppression (CIM) and reviews management strategies for patients that might develop neutropenia while on chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

In this companion article, Dr Luis Raez provides insights into effective management patients with extensive-stage small cell lung cancer who develop chemotherapy-induced myelosuppression.